X

The Envigo brand story

At Envigo, we are proud of our customer-centric culture which makes us responsive to every customer, no matter their size, continually optimizing their research programs to ensure consistently clear results. Learn more

Corporate social responsibility

Corporate social responsibility (CSR) has always been part of the way we’ve done business—it's what we do and how we do it. Learn more

Press release

Avista Healthcare Public Acquisition Corp., a publicly traded special purpose acquisition company, and Envigo International Holdings, Inc., a leading early stage non-clinical contract research organization offering a diverse set of non-clinical discovery and safety assessment services as well as laboratory animal science tools, jointly announced that they have entered into a definitive merger agreement. Read more

Avista Healthcare Public Acquisition Corp. to combine with Envigo International Holdings, Inc.

Avista Healthcare Public Acquisition Corp., a publicly traded special purpose acquisition company, and Envigo International Holdings, Inc., a leading early stage non-clinical contract research organization offering a diverse set of non-clinical discovery and safety assessment services as well as laboratory animal science tools, jointly announced that they have entered into a definitive merger agreement. Read More

New appointments strengthen Envigo’s position as a leading regulatory consultancy

Envigo has bolstered its regulatory consultancy expertise with the addition of four new influential hires and an additional geographic focus for existing teams. Read More

Teklad Diets recertified to new ISO standard

Envigo has announced that its Teklad Diets sites in Madison, WI received recertification to the new ISO9001:2015 standard. Read More

See All Latest News
Brochure
Envigo oncology brochure (USA | EU)

At Envigo, we understand that our customers conduct research and develop products that have the potential to offer significant improvements to global health and the environment. We also realize achieving that potential has grown more challenging. That is why we remain focused on your goals, needs and expectations, ensuring you have a trusted partner to advance your life-changing research and products.

Article
Developments in LifeSciences Vol. 15, No. 1

In this issue:
• 20 critical questions for ensuring inhaled crop protection and chemical registration
• The CRO landscape — An evolving safety testing market
• Substance identity: The critical component of both lead and co-registrant dossiers
• The extended one-generation reproductive toxicity study (EOGRTS), OECD test guideline 443

Webinar on-demand
Key considerations in the safety evaluation of drugs targeting immune checkpoints

Presented by Lee Coney (Chief Scientific Officer - Biologics) and Mandy Horn (Supervisor - Veterinary Science, Research and Support). You will learn what is cancer immunotherapy; what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?; Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets; and more.

See all insights